LambdaVision, a CT-based biotech company developing a protein-based artificial retina technology, closed its first Seed funding.
The round was led by Aurelia Foundry Fund, a fund spun out of MIT. Other investors included Boryung, a publicly listed Korean pharmaceutical company, and E2MC Ventures.
The company intends to use the funds to accelerate its GMP manufacturing scale up and IND-enabling efficacy and toxicity studies, advancing to clinical trials initially targeted for blind patients with advanced retinitis pigmentosa (RP).
Led by Nicole Wagner, Ph.D., CEO, LambdaVision is developing a protein-based artificial retina to restore meaningful vision for the millions of patients blinded by retinal degenerative diseases, including retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Its patent-protected artificial retina technology uses photoactive proteins to naturally mimic the light-absorbing properties of human photoreceptor cells and activate neuroreceptors still present in degenerated retinas of blind patients.
